乳腺癌组织hsa-mir-337表达降低的临床意义与预后分析

doi:10.3969/j.issn.1005-6483.2022.04.013

临床外科杂志 ›› 2022, Vol. 30 ›› Issue (4): 345-348.doi: 10.3969/j.issn.1005-6483.2022.04.013

乳腺癌组织hsa-mir-337表达降低的临床意义与预后分析

061100 河北省黄骅市中医医院外科(金一);河北医科大学(王昕仪、杜润森)；河北医科大学第一医院普外科(郑丽华、杨艳)，创伤外科(赵亚恒)

收稿日期:2021-06-23 接受日期:2021-06-23 出版日期:2022-04-20 发布日期:2022-04-20
通讯作者: 杨艳，Email：zhenglihua23@outlook.com

Decreased expression of hsa-mir-337 predicts poor prognosis in patients with breast cancer

Department of Surgery,the First Hospital of Hebei Medical University,Shijiazhuang 061100, China

Received:2021-06-23 Accepted:2021-06-23 Online:2022-04-20 Published:2022-04-20

摘要/Abstract

摘要： 目的分析hsa-mir-337表达在判断乳腺癌病人预后的作用。方法利用人类肿瘤基因组(TCGA)数据库下载乳腺癌miRNA测序数据及其对应的临床病理资料，使用R软件进行数据分析。Cox单因素回归分析与不良预后相关的miRNAs，对差异表达中有意义的miRNAs进行Cox多因素回归分析,建立风险评估模型，使用基因富集方法(GSEA)预测hsa-mir-337的调控基因。结果 hsa-mir-337低表达病人的总生存期低于高表达。Cox比例风险模型的多变量分析表明hsa-mir-337(HR=0.981062,P<0.001)可以作为乳腺癌的独立预后因素。结论 hsa-mir-337可成为预测乳腺癌预后的有效生物标志物。

关键词: 乳腺癌, hsa-mir-337, 癌症基因组图谱, 预后

Abstract: Objective To identify the prognostic role of hsa-mir-337 in breast cancer.Methods The TGGA database was used to gain miRNA-seq expression as well as clinical data.R software was used for data analysis.Univariate Cox analysis as well as Multivariate Cox analysis were used to identify the prognostic significance of hsa-mir-337 in BREAST CANCER patients.GSEA was performed to analyze the functional annotation of the predicted genes. Results Hsa-mir-337 was significantly associated with overall survival(OS)of BREAST CANCER.The low expression group had worse OS compared to the high expression group.Through Multivarite analysis with Cox proportional hazards model indicated that hsa-mir-337(HR=0.981062,P<0.001) was independent progonostic factor for patients with breast cancer. Conclusion Hsa-mir-337 was identified as an independent factor in the prognosis of breast cancer.

Key words: breast cancer, hsa-mir-337, the cancer genome atlas, prognosis

金一王昕仪杜润森郑丽华赵亚恒杨艳. 乳腺癌组织hsa-mir-337表达降低的临床意义与预后分析[J]. 临床外科杂志, 2022, 30(4): 345-348.

JIN Yi , WANG Xinyi, DU Runsen, et al. Decreased expression of hsa-mir-337 predicts poor prognosis in patients with breast cancer[J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(4): 345-348.

参考文献

相关文章 15

[1]	杨恒张军郭强林称意罗卫民原野程栋梁罗湘玉刘华郭家龙. 基于多数据库分析HLA-DPB1在肺腺癌中的潜在价值[J]. 临床外科杂志, 2022, 30(4): 339-344.
[2]	王鹏远尚义超郑铎尚攀峰岳中瑾. 肾盂癌与输尿管癌术后预后分析[J]. 临床外科杂志, 2022, 30(4): 368-371.
[3]	金成龙张建国. 乳腺癌新辅助化疗后前哨淋巴结活检的研究进展[J]. 临床外科杂志, 2022, 30(4): 386-389.
[4]	曹思旸刘霞朱丽璋刘晓岭钟洁愉孙德胜韦伟. 吲哚菁绿联合亚甲蓝在早期乳腺癌前哨淋巴结活检中应用的荟萃分析[J]. 临床外科杂志, 2022, 30(3): 239-243.
[5]	卢开进申江峰贾卫光. 胸腔镜改良喉返神旁经淋巴结清扫治疗食管癌的疗效及对预后的影响[J]. 临床外科杂志, 2022, 30(3): 257-260.
[6]	沈荐李敏哲杜燕夫. 中心型肥胖对腹腔镜远端胃癌D2根治术临床疗效的影响[J]. 临床外科杂志, 2022, 30(3): 261-265.
[7]	李玉柱夏连杰. 膀胱癌病人癌组织中Dickkopf相关蛋白2的表达及与预后的相关性[J]. 临床外科杂志, 2022, 30(3): 280-283.
[8]	季金涛康波苏燕胜. 前列腺特异性膜抗原在前列腺癌组织中的表达与临床病理特征的关系及预后价值[J]. 临床外科杂志, 2022, 30(2): 130-133.
[9]	袁泳锨庾建中王永霞. 乳腺癌细胞外泌体miR-27a对巨噬细胞极化及肿瘤生长和转移的影响[J]. 临床外科杂志, 2022, 30(2): 149-154.
[10]	马强杨丽何建信张春霞郝金燕. T1～2期人表皮生长因子受体2阳性型及非阳性型浸润性乳腺癌微钙化特点比较[J]. 临床外科杂志, 2022, 30(2): 156-159.
[11]	李云龙杜正华张慧敏解凤妮李纪鹏. 胃肠胰神经内分泌肿瘤临床治疗及预后分析[J]. 临床外科杂志, 2022, 30(2): 166-170.
[12]	毛艳王海波. 2021.V5 NCCN 临床实践指南：乳腺癌新辅助治疗更新解读[J]. 临床外科杂志, 2022, 30(1): 23-26.
[13]	张明坤王哲杨柳侯兰张聚良. 黏液性乳腺癌的预后影响因素分析与预后模型构建[J]. 临床外科杂志, 2022, 30(1): 44-50.
[14]	孙政阙海峰楼建徐宏涛. 营养风险指数在Ⅳ期胃癌预后评价中的意义[J]. 临床外科杂志, 2022, 30(1): 58-61.
[15]	周蓓樊利春吴沉昊王婧. TSPAN13在乳腺癌组织中的表达及与临床病理特征的关系[J]. 临床外科杂志, 2021, 29(9): 834-837.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

乳腺癌组织hsa-mir-337表达降低的临床意义与预后分析

Decreased expression of hsa-mir-337 predicts poor prognosis in patients with breast cancer

PDF (PC)

PDF (Mobile)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0